Adverse prognostic factor ID'd in operable breast cancer

October 30, 2012
Adverse prognostic factor ID'd in operable breast cancer
For women with operable breast cancer, moderate immunohistochemical expression of human epidermal growth factor receptor (HER)-2 (2+) without amplification of HER-2 is an adverse prognostic factor, according to a study published online Sept. 4 in The Oncologist.

(HealthDay)—For women with operable breast cancer, moderate immunohistochemical expression of human epidermal growth factor receptor (HER)-2 (2+) without amplification of HER-2 (HER-2 2+/HER-2) is an adverse prognostic factor, according to a study published online Sept. 4 in The Oncologist.

Valentina Rossi, M.D., from the Institute for Cancer Research and Treatment in Candiolo, Italy, and colleagues compared the clinical outcomes of 1,150 women (median age, 58 years) with operable breast cancer who were not receiving adjuvant . Patients were stratified according to a common HER-2 testing algorithm.

Of the women, 40 percent were considered HER-2 0+; 39 percent were HER-2 1+; 10 percent were HER-2 2+/HER-2; and 11 percent were HER-2+ (3+ or HER-2+) by fluorescence in situ hybridization. The researchers found that, on multivariate analysis, a HER-2 2+/HER-2 status correlated with worse disease-free survival, compared with a HER-2 0 or 1+ status. A HER-2 2+/HER-2 status showed a time-dependent effect on the probability of disease-free survival, with an initial advantage that lessened every year by a factor of 1.649, compared with a HER-2+ status.

"A HER-2 2+/HER-2status is an adverse prognostic factor in patients with operable ," the authors write. "Because of suggestions from randomized trials that the benefits of adjuvant trastuzumab may not be limited to patients with HER-2+ tumors, patients with a HER-2 2+/HER-2status are ideal candidates for studies testing this hypothesis."

One author disclosed financial ties to the pharmaceutical industry.

Explore further: Taxane-induced neuropathy not tied to breast cancer outcome

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Taxane-induced neuropathy not tied to breast cancer outcome

August 2, 2012

(HealthDay) -- For patients with operable breast cancer, peripheral neuropathy due to adjuvant taxane therapy does not correlate with improved outcomes, according to research published online July 30 in the Journal of Clinical ...

Lymphovascular invasion is independent predictor of survival

July 29, 2012

(HealthDay) -- In patients with invasive breast cancer, lymphovascular invasion (LVI) is a strong and independent predictor of both breast cancer-specific survival (BCSS) and distant metastasis-free survival (DMFS), according ...

Recommended for you

Dogs detect breast cancer from bandage: researchers

March 24, 2017

Dogs can sniff out cancer from a piece of cloth which had touched the breast of a woman with a tumour, researchers said Friday, announcing the results of an unusual, but promising, diagnostic trial.

'Jumonji' protein key to Ewing's sarcoma rampage

March 24, 2017

By the time Ewing's Sarcoma is diagnosed, primarily in teens and young adults, it has often spread from its primary site to other parts of the body, making it difficult to treat. A University of Colorado Cancer Center study ...

In a sample of blood, researchers probe for cancer clues

March 24, 2017

One day, patients may be able to monitor their body's response to cancer therapy just by having their blood drawn. A new study, led by bioengineers at UC Berkeley, has taken an important step in that direction by measuring ...

Researchers gain insight into breast cancer drug resistance

March 24, 2017

Breast cancer's ability to develop resistance to treatment has frustrated researchers and physicians and has thwarted even the latest and greatest targeted therapies. For example, after researchers identified a disease pathway ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.